Targeting PCSK9 for Therapeutic Gains

Current Atherosclerosis Reports

Volumn 17, Issue 4, 2015, Pages

  Shapiro, Michael D ^a   Fazio, Sergio ^a   Tavori, Hagai ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Lipoprotein (a); Low density lipoprotein; Low density lipoprotein receptor; Pleiotropic effects; Proprotein convertase subtilisin kexin 9; Triglycerdies

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN B100; ATORVASTATIN; BOCOCIZUMAB; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMA PROTEIN; PROTEIN PCSK9; ROSUVASTATIN; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; ENZYME DEFICIENCY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; MULTICENTER STUDY (TOPIC); MYALGIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; DYSLIPIDEMIAS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; HYPERCHOLESTEROLEMIA; MOLECULAR TARGETED THERAPY; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84923843937     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-015-0499-4     Document Type: Review

References (61)

1. Abifadel M et al. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep. 2014;16(9):439. This report documents the sequence of events from the initial discovery of the third locus of autosomal dominant hypercholesterolemia, PCSK9, to its development as a promising target of pharmacotherapy to reduce atherosclerotic cardiovascular disease events.
2. Abifadel M et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6.
3. Zhang DW et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282(25):18602–12.
4. Cohen J et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–5.
5. Cohen JC et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72.
6. Hooper AJ et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193(2):445–8.
7. Fasano T et al. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol. 2007;27(3):677–81.
8. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11(10):563–75.
9. Rashid S et al. PCSK9 promotes intestinal overproductin of triglyceride-rich apolipoprotien-B liporptoein throug both LDL-receptor dependent and independent mechanisms. Circulation. 2014;130(4):431–41.
10. Levy E et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis. 2013;227(2):297–306.
11. Le May C et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009;29(5):684–90.
12. Raal FJ et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63(13):1278–88. This pooled-analysis assessed the effect of evolocumab on Lp(a) from 4 phase II trials. Evolocumab treatment for 12 weeks reduced Lp(a) by 25-30% (dose-dependent) compared to control.
13. Gaudet D et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;114(5):711–5.
14. Raal, F.J., et al., Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. The Lancet, (0). This study demonstrated the potential utility of PCSK9 inhibition in patients with genetically proven homozygous familial hypercholesterolemia. On average, evolocumab lowered LDL-C by 31% versus placebo. The results established a clear relationship between the underlying LDL receptor mutation (defective vs. null) and LDL-C reduction with evolocumab.
15. Stein EA et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113–20.
16. Cully M. Dyslipidaemia: RNAi targeting PCSK9 decreases lipid levels in a human trial. Nat Rev Cardiol. 2013;10(12):682.
17. Schwartz GG et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. Am Heart J. 2014;168(5):682–689.e1.
18. Roth, E.M., et al., A 24-Week study of Alirocumab as Monotherapy versus ezetimibe: the first phase 3 data of a proprotein convertase subtilisin/kexin type 9 inhibitor. J Am Coll Cardiol, 2014. 63(12_S).
19. Kastelein JP et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014;28(3):281–9.
20. Ginsberg, H.N., et al., ODYSSEY HIGH FH: Efficacy and Safety of Alirocumab in Patients With Severe Heterozygous Familial Hypercholesterolemia, in Circulation. 2014.
21. Robinson, J., et al., Long-term safety, tolerability and efficacy of alirocumab versus placebo in high cardiovascular risk patients: first results from the ODYSSEY LONG TERM study in 2,341 patients Eur Heart J, 2014. 35. This study demonstrated the long-term (52 weeks) tolerability and efficacy of alirocumab. A post-hoc analysis suggested a statistically significant 54 % reduction in major adverse cardiovascular events with alirocumab (p < 0.01). The investigators also confirmed the safety in subjects achieving an LDL-C <25 mg/dL.
22. Robinson, J., et al., Long-term Safety, Tolerability and Efficacy of Alirocumab versus Placebo in 2,341 High Cardiovascular Risk Patients: ODYSSEY LONG TERM Circulation, 2014. 130. This study demonstrated the long-term (52 weeks) tolerability and efficacy of alirocumab. A post-hoc analysis suggested a statistically significant 54 % reduction in major adverse cardiovascular events with alirocumab (p < 0.01). The investigators also confirmed the safety in subjects achieving an LDL-C <25 mg/dL.
23. Moriarty PM et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. Circulation. 2014;130.
24. Moriarty PM et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8(6):554–61.
25. Guyton JR et al. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72–81.
26. Bays H et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II. Circulation. 2014;130.
27. Robinson JG et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS studies. Clin Cardiol. 2014;37(10):597–604.
28. Colhoun H et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord. 2014;14(1):121.
29. Kereiakes DJ et al. Efficacy and dafety of alirocumab in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO I study. Circulation. 2014;130.
30. Cannon CP et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study. Eur Heart J. 2014;35.
31. Koren MJ et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531–40.
32. Blom DJ et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–19.
33. Robinson JG et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on ldl-c lowering in patients with hypercholesterolemia: The laplace-2 randomized clinical trial. JAMA. 2014;311(18):1870–83.
34. Stroes E et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–8.
35. Raal, F.J., et al., PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. The Lancet, (0).
36. Weinreich M, Frishman WH. Antihyperlipidemic therapies targeting PCSK9. Cardiol Rev. 2014;22(3):140–6.
37. Gumbiner BM et al. Effects of 12 weeks of treatment with RN316 (PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects on high and maximal dose statins. Circulation. 2012;126.
38. Ballantyne, C.M., et al., Efficacy and safety of Bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase Subtilisin/Kexin type 9 in statin-treated Hypercholesterolemic subjects: results from a randomized, placebo-controlled, dose-ranging study (NCT: 01592240). Journal of the American College of Cardiology, 2014. 63(12_S).
39. McKenney JM et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344–53.
40. Roth EM et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891–900.
41. Stein E et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29–36.
42. Giugliano RP et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007–17.
43. Koren MJ et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995–2006.
44. Raal F et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408–17.
45. Sullivan D et al. Effect of a monoclonal antibody to pcsk9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the gauss randomized trial. JAMA. 2012;308(23):2497–506. GAUSS-2 evaluated the efficacy of evolocumab in patients with statin intolerance. Subjects treated with evolocumab received significantly greater LDL-C lowering as compared to those who treated with ezetimibe. Treatment with evolocumab was associated with a lower incidence of myalgia than with ezetimibe (16 [8%] versus 18 [18%]). This finding is consistent with the idea that statin-induced myalgias are not related to low plasma LDL-C levels.
46. Stein EA et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108–18.
47. Dias CS et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60(19):1888–98.
48. Group HTC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–91.
49. Boden W et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.
50. Albers JJ et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with Low HDL/high triglyceride and impact on global health outcomes). J Am Coll Cardiol. 2013;62(17):1575–9.
51. Poirier S et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283(4):2363–72.
52. Roubtsova A et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 2011;31(4):785–91.
53. Zaid A et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48(2):646–54.
54. Rashid S et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005;102(15):5374–9.
55. Fitzgerald K et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383(9911):60–8.
56. Tavori H et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 2013;127(24):2403–13.
57. Kosenko T et al. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem. 2013;288(12):8279–88. This study disecte and prove the exsitance of reciprocal regulation between PCSK9 and LDLR and suggset clinical implications to this novel regulatory mechanims. In addition, this report use multiole methodologies to show that signigcantproprotion of the active form of PCSK9 is cerried by the LDL particle.
58. Sun H et al. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol. 2012;32(7):1585–95.
59. Stein EA et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126(19):2283–92.
60. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262–8.
61. Tavori H et al. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circ Res. 2013;113(12):1290–5. The first report to show that there is a loss of more than 50% of serum PCSK9 during lipoprotien aphereisis - a defenite proof that LDL-PCSK9 assocaition in humans may have clinical implication.